VRAX
Virax Biolabs Group Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$2.54
+0.40%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 145.71x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.27x
- Price / sales
- 144.28x
- Price / cash flow
- -0.27x
Enterprise value
- Enterprise value
- -$4.3M
- EV / sales
- -308.02x
- EV / EBITDA
- 0.55x
- EV / EBIT
- 0.48x
- Market cap
- $2.0M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026